Skip to main content
spacbrain

Vincerx Pharma

Closed (deSPAC)

Profile in progress

What it is
PHARMA, INC
What it’s doing now
Merging with LifeSci Acquisition Corp. (LSAC) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

PHARMA, INC. Vincerx Pharma, Inc. (Vincerx) is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage modular bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates. For more information, please visit www.vincerx.com . CAUTIONARY STATEMENT This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx’s business model, capital requirements and sufficiency of

What the company says about itself

Web research — not audited
What our web check found

[WEB-INTEL 2026-09-02] 7 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vincerx Pharma has raised a total of $50M from 1 Post IPO round on Sep 16, 2021." [https://tracxn.com/d/companies/vincerx-pharma/__HtOxjMzbsk8CNwc0Hbriy80VszJZu9O4kTl0J-S8t_4/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The company received notice from Nasdaq on April 14, 2025, citing non-compliance with the minimum bid price requirement of $1.00 per share over 30 consecutive business days." [https://www.stocktitan.net/news/VINC/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-x6upqqnwxtd7.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Trading of Vincerx's common stock was inadvertently suspended on April 16, 2025, but will resume on April 21, 2025, before being permanently suspended on April 23, 2025." [https://www.stocktitan.net/news/VINC/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-x6upqqnwxtd7.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The company plans to file a Form 25 for delisting around April 28, 2025." [https://www.stocktitan.net/news/VINC/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-x6upqqnwxtd7.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "As of 01-Sep-2026, Vincerx Pharma's stock price is $0.01. Its current market cap is $68.6K." [https://pitchbook.com/profiles/company/439803-82] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "As of 31-Mar-2025, Vincerx Pharma has a trailing 12-month revenue of null." [https://pitchbook.com/profiles/company/439803-82] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vincerx Pharma's most recent deal was a Merger/Acquisition with LifeSci Acquisition. The deal was made on 23-Dec-2020." [https://pitchbook.com/profiles/company/439803-82]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Vincerx Pharma is merging with LifeSci Acquisition Corp. (LSAC) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $51M · unsourced

Structure per SEC accession(s) 0001193125-21-275176, 0001193125-20-310869. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Vincerx Pharma going public?

Vincerx Pharma has an approved merger with the SPAC LifeSci Acquisition Corp. (LSAC). Deal status: Closed (deSPAC).

Does Vincerx Pharma have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.